B. Riley Strengthens Position as Leading Small- and Mid-Cap Broker-Dealer with Key Additions to Equity Research Division

Return to Wealth Management Media Center

(LOS ANGELES, July 28, 2020)

B. Riley (NASDAQ: RILY) today announced key changes to its equity research division, strengthening the firm's leading position as a full-service investment bank serving the small- and mid-cap space. Mayank Mamtani was promoted to Senior Analyst and Group Head of Healthcare Research, Justin Zelin joins as Biotech Research Analyst, and Chris Souther joins as a Research Analyst focused on Clean Technology and Sustainable Energy.

"We continue to invest in our award-winning research platform with an aim to be Wall Street's leading source of differentiated small- and mid-cap coverage. Mayank's Healthcare Group Head appointment comes amidst unprecedented industry disruption caused by the COVID-19 pandemic and follows our recent successful Virtual Infectious Disease Summit. We are also pleased to welcome Justin and Chris as the evolving Healthcare and Clean Energy industries remain a large source of undervalued and misunderstood investment ideas with outsized return potential," said Craig A. Ellis, Director of Research with the institutional broker-dealer subsidiary of B. Riley Financial. "We remain committed to investing resources to help clients and partners best capitalize on proprietary small- and mid-cap investment opportunities."

Mayank Mamtani was promoted to Senior Analyst and Group Head of Healthcare Research. He joined B. Riley as a Research Analyst in 2018 and covers biotechnology companies pioneering cutting-edge therapeutics innovation in liver diseases, hematology-oncology, and infectious diseases. Mamtani is one of the leading voices on prophylactic innovations for cholesterol management and novel coronavirus (COVID-19), aimed at reducing the significant burden on global healthcare systems in chronic and acute settings, respectively. He ranks in the top 5% of all analysts tracked by TipRanks. His prior experiences with Amgen and Leerink Partners, coupled with graduate-level training in biotechnology from Carnegie Mellon University, have played an instrumental role in his ability to add significant value to B. Riley's fast-growing healthcare franchise.

Justin Zelin joins B. Riley as a Biotech Analyst focused on breakthrough cellular and genetic medicines. He was previously an influential contributor with increasing responsibilities within the biotech equity research teams at Canaccord Genuity, SVB Leerink, and Oppenheimer & Co, where he covered over 45 small and mid-cap companies focused on oncology, genetic medicines, and rare diseases. Zelin is a formally trained scientist and has worked on immuno-oncology and infectious disease therapeutic development in both academic and industry labs including Agenus, Harvard University, and Brigham and Women's Hospital. He holds a master's degree in Biotechnology and a bachelor's degree in biology from Harvard University. He is based in New York.

Chris Souther, CFA, joins B. Riley as a Research Analyst focused on sustainable energy and clean technology. He previously was on Cowen and Company's sustainable energy and industrial technology team for four years, where he covered more than 30 small-, mid-, and large-cap companies across a range of subsectors, including solar, automotive technology, fuel cells, energy storage, wind, geothermal, lighting, natural gas technology, and bioproducts. Prior to Cowen, he held roles in wealth and investment management, and equity capital markets and investor relations at HighTower and Aegis Capital. He received a bachelor's degree in Economics from Fordham University and is based in New York.